Drug intelligence / Profile preview

eN-Lac

Development stage: Phase 3
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

eN-Lac is a probiotic capsule containing the specific strain Lactobacillus paracasei GMNL-32. It has been investigated for its efficacy and safety in treating children with perennial allergic rhinitis (PAR). Additionally, studies have shown its immunomodulatory functions, including enhancing natural killer cell activity and lymphocyte proliferation.

Brand names: eN-Lac
Other names: Lactobacillus paracasei GMNL-32

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)FAS (Tumor necrosis factor receptor superfamily member 6)

Beyond the preview

Go deeper on eN-Lac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eN-Lac.

Explore the full profile